

RHEUMATOLOGY QUESTIONNAIRE

Your help completing this questionnaire would be appreciated and should save you some time at your forthcoming Rheumatology appointment. This information is confidential. Please complete in the weeks prior to your clinic appointment. If you feel you cannot adequately complete any part, don't worry as it can be discussed with you at your appointment. Please give this sheet to the doctor at the clinic

Name SHONA HALLIDAY D.O.B. 6.11.1975

Address 16 THORNYBANK Tel No.

GROVE, DALKEITH G.P. Dr. Robertson

EH22 2EG

Occupation (if retired, previous occupation) COOK - House Wife

Past Medical/Surgical History

Please list below details of any previous operations or serious illnesses.

Previous Operation/Illness	Date	Where were you treated ?
<u>Tonils removed</u>	<u>APX 1995</u>	<u>ROYAL</u>
<u>C-section</u>	<u>AUG 2011</u>	<u>ROYAL</u>
.....		
.....		

Family History

Does anyone in your family have arthritis ? Yes/No

If yes, please give details

Relationship to you	Type of Arthritis
.....	
.....	

Does anyone in your family have psoriasis ? Yes/No

If yes, what is there relationship to you

.....

Current Medication

Dose

iron tablets

3 per day

anti depressants

75mg + 37.5mg daily

Are you allergic to any medication ?

~~Yes~~/No

Details :
.

Social History

Do you smoke ?

Yes/~~No~~

If no, have you smoked in the past ?

Yes/No

What is your average weekly alcohol intake ?

5 units

Thank you for completing this form. Please remember to bring it with you to your appointment.

Date : 8.10.12

HYDROXYCHLOROQUINE ADULT CHECKLIST

Patient Name: *WT 776*
Patient D.O.B: *5/10/17 1/11/11 1/11/11*
Patient number: *6/11/15*

INVESTIGATIONS BEFORE STARTING HYDROXYCHLOROQUINE

1. BLOOD TEST : full blood count / renal & liver function / ESR
2. BASE LINE VISUAL ACUITY & AMSLER TEST
3. WEIGHT

INVESTIGATIONS WHILST TAKING HYDROXYCHLOROQUINE

EYE TEST: VISUAL ACUITY & AMSLER TEST. 6-12 MONTHLY.

- ☒ Purpose of drug: Damps down inflammation, thus reduces pain, stiffness and swelling. May reduce the rash in Systemic Lupus Erythematosus. This drug is used in differing doses for the treatment of malaria, so caution needed for internet research.
- ☒ Appearance: round enteric coated tablet. Dose: Advised by consultant or GP depending on weight. To be taken with or after food. Depending on response, dose may be reduced accordingly to achieve maintenance dose. Medics to advise. *400mg daily*
- ☒ Response to the drug: Does not take effect immediately. Initially 8-12 weeks & up to 6 months to reach optimum effect. If beneficial, and no adverse side effects experienced, may be taken for any length of time.
- ☒ Side effects: Uncommon. Occasionally, Skin rashes/ Indigestion / Headaches / Diarrhoea. May settle spontaneously, if not, seek advice from GP. Dose may be temporarily adjusted.
- ☒ Research indicates potential risk that the retina may be affected. Blurred vision may occur initially. Beware of driving and using machinery. Seek medical advice if symptoms apparent.
- ☒ Explain necessity for above investigations. Ensure all base line tests complete prior to administration of medication.
- ☒ Continue other medication as directed by GP. Compatible with non-steroidal anti inflammatory drugs, if blood monitoring maintained.
- ☒ Indigestion remedies may prevent the drug from being absorbed. Seek advice first from pharmacist or GP for 'over the counter' preparations
- ☒ Immunisations - Compatible. Pneumococcal / flu / swine flu vaccines: recommended
- ☒ Alcohol: in moderation.
- ☒ Pregnancy: Prior to conceiving seek medical advice. DO NOT Breastfeed.
- ☒ Alternative containers are available from your pharmacist if you have difficulty with screw tops.
- ☒ Verbal and written information given to patient re: Hydroxychloroquine. And complete drug counselling form & give to patient.
- ☒ Contact number of Nurse Specialist help line given to patient.

DATE: *17/2/14*

SIGNATURE: *S. Holliday*

METHOTREXATE ADULT CHECKLIST

Patient Name *Shirley Murray*

Patient D.O.B

6/11/75

Patient number

INVESTIGATIONS BEFORE STARTING METHOTREXATE

1. BLOOD TEST : full blood count (Including differential white cell count), renal & liver function / ESR
2. CHEST XRAY : Result will be confirmed by consultant or registrar & sent to GP prior to prescribing.

INVESTIGATIONS NEEDED WHILST TAKING METHOTREXATE

1. BLOOD TESTS : As above. Fortnightly until stable for 6 weeks, then monthly.

FOR YOUR NEXT FOLLOW UP APPOINTMENT, IF POSSIBLE PLEASE BRING A RECENT TEST RESULT FROM YOUR GP FOR THE FOLLOWING URINE TEST / BLOOD PRESSURE / BMI THANK YOU

- ☒ Purpose of drug: Has an effect on the immune system, slowing the progression of the disease. Thus dampens down inflammation, reduces pain, stiffness and swelling. This drug is used in differing doses for the treatment of cancer, so caution needed for internet research.
- ☒ Dose: to be prescribed by Consultant. To be taken ONCE WEEKLY with food. The dose may gradually increase until prescribed maintenance dose achieved. Issue and explain drug therapy chart.
- ☒ A 10mg strength tablet is available and sometimes used for other conditions. Methotrexate should only be prescribed & dispensed as 2.5mg strength. As the two strengths are very similar in appearance, and may lead to drug errors. Please always check that your dose is correct before taking it each week.
- ☒ Response to the drug: Does not take effect immediately. From 6-8 weeks to 6 months to reach optimum effect. May be taken for any length of time, if proves beneficial, and no adverse side effects experienced.
- ☒ Folic Acid 5mgs will be prescribed to help counteract side effects. Taken, 24hrs after Methotrexate.
- ☒ Side effects: Nausea, mouth ulcers, skin rash, diarrhoea, hair loss, possible. May settle spontaneously, if not, seek advice from GP. Dose may be temporarily adjusted. Rarely causes inflammation of the lungs, causing dry cough, breathlessness, or flu like symptoms. If occurs, **STOP** immediately and seek medical advice. There is an increased risk of developing lymphoma (blood cancer) when taking low dose methotrexate. The development of this condition is also associated with rheumatoid arthritis itself.
- ☒ May affect the blood count, potential for problems with healing, and risk of infection. Monitor general health and seek advice accordingly from Gp. It is necessary to **STOP** taking methotrexate if antibiotics prescribed, infection identified, or surgery required. Inform medics & dentist prior to invasive treatments.
- ☒ Explain necessity for above investigations. Ensure all base line tests complete.
- ☒ Continue other medication as directed by GP. Compatible with non-steroidal anti inflammatory drugs, blood monitoring to be maintained. Seek advice from pharmacist for 'over the counter' preparations.
- ☒ Report contact with chicken pox / shingles to GP. Antiviral treatment may be prescribed.
- ☒ Pneumococcal / flu vaccines: RECOMMENDED. LIVE vaccines – INCOMPATIBLE.
- ☒ Alcohol – NO SPIRITS, 5-6 glasses of wine or 2-3 pints of lager per week, due to potential effect on liver.
- ☒ AVOID Pregnancy; contraception needed for males & females during treatment and for at least 3 months after treatment discontinued. DO NOT Breastfeed.
- ☒ There are alternative containers available from your pharmacist if you have difficulty with screw tops.
- ☒ Verbal and written information given to patient re: Methotrexate. Drug counselling check list completed, & issued to patient.
- ☒ Contact number of Nurse Specialist help line given to patient.

DATE: *17/2/16*

SIGNATURE:

G. Halliday

CHECKLIST FOR PATIENTS STARTING ON SULPHASALAZINE

Purpose of giving drug: damps down inflammation in arthritis.

☐

Appearance and dose:

Each tablet is 500mg. Largish tablet. Start with small dose to minimise side-effects - headache/nausea. Explain enteric-coating.

☐

Reduce dose and hold for 1 week if headache/nausea, then restart.

Aim for 4 tablet per day (2x2) once established unless told otherwise.

☐

May colour urine orange, normal and harmless.

☐

Continue other medication as directed by GP.

☐

Time scale for starting to feel benefit: may take 4-8 weeks.

☐

Side effects: Nausea and headaches are the commonest side-effects and can be overcome by adjustment of the dose. Occasionally skin rash, mouth ulcers, diarrhoea and dizziness. Rarely adverse effects on the lung or liver may occur. A reduction in the blood count can occur but uncommon. Ensure patient reads information sheet. Report any other possible side-effects to GP.

☐

Any other side effects on blood or liver picked up on routine blood sample taken by GP, monthly for the first three months then once every three months. GP will check and record blood results.

☐

Drug interaction: Double check for aspirin or sulphonamide allergy/sensitivity. Do not take over-the-counter preparations, discuss this first with your GP, nurse or pharmacist.

☐

In men the sperm count may fall temporarily during treatment. If you are planning a family or become pregnant while receiving Sulphasalazine, you should discuss this with your GP or Rheumatologist as soon as possible.

☐

Alcohol can be taken in moderation when receiving Sulphasalazine.

☐

GP gives prescription to patient who gets tablets from chemist. If difficulty with screw-tops ask chemist for non-childproof container.

☐

Give information sheet and blood sheet to patient and explain what they are. Blood results recorded on sheet by GP. Patient to retain card and bring it with them when they come back to the clinic.

☐

How long can you be on Sulphasalazine? As long as helping and no adverse side effects.

☐

Verbal and written information given to patient commencing on Sulphasalazine.

☐

Contact number of nurse specialist given to patient.

☐

O.P. CLINICAL NOTES

(Medical)

NUMBER

NAME

DATE

8/10/11

RHEUMATOLOGY - DR GRAY

E. BRIAN
STU. NURSE

BP: 104/48

P: 80

WEIGHT: 70

HEIGHT: 165

BMI: 25

SOB:

(BC)

Rt hand

For years. 4-5 yrs

knew arm, pulled arm.

11/3/12

left leg, wrist, and knee, hip.

11/1/12

long toe, 1st, middle

EMSI Smiths. act.

CCP 334

Thyroxine - helps. MS. 400g

Iron Tablet.

ESR 25

vent place.

11/1/12

no hair on nose, no eyelids

→ no mouth, no teeth, no pharynx

new 75

→ no mucus, no hyal.

11/1/12

→ no skin, no hair.

→ no skin tight

→ no heart, no lungs.

→ no nose, no pharynx

→ no kidneys.

→

no pharynx.

Full time. now, 1/2, 200g. 200g

100g. 100g.

2 child x 100g. 100g.

100g. 100g.

94

no syn to
no OA
norm.

(G)
(C)

mr. Palko RA.

Ph

3.2.4. Dr McKay

LK 77 kg

Ht 165 cm

B/P 116 / 68 P95

(L) green bar

S/W closed

erased, Symonby

upheld

Stem

+ anaesthesia

Mr
Mr

Halliday, Shona

16 Thornybank grove,

Dalkeith,

Midlothian,

EH22 1AP

CHI 0611751143

77197 S Ahmed

HEALTH ASSESSMENT QUESTIONNAIRE (HAQ)

Date: 3/2/14Patient name: S Ahmed

Please tick the response which best describes your usual abilities over the past week

Without ANY
difficulty⁰With SOME
difficulty¹With MUCH
difficulty²UNABLE
to do³CATEGORY
SCORE

1. DRESSING and GROOMING (D)

Are you able to:

a. Dress yourself, including tying
shoelaces and doing buttons?☒☐☐☐☐

b. Shampoo your hair?

☒☐☐☐

2. ARISING (A)

Are you able to:

a. Stand up from an armless
straight chair?☒☐☐☐☐

b. Get in and out of bed?

☒☐☐☐

3. EATING (E)

Are you able to:

a. Cut your meat?

☒☐☐☐☐

b. Lift a full cup or glass to your mouth?

☒☐☐☐c. Open a new carton of milk
(or soap powder)?☒☐☐☐

4. WALKING (W)

Are you able to:

a. Walk outdoors on flat ground?

☒☐☐☐☐

b. Climb up five steps?

☒☐☐☐

PLEASE TICK ANY AIDS OR DEVICES THAT YOU USUALLY USE FOR ANY OF THESE ACTIVITIES:

Cane (W)

☐

Walking frame (W)

☐

Built-up or special utensils (E)

☐

Crutches (W)

☐

Wheelchair (W)

☐

Special or built-up chair (A)

☐

Devices used for dressing (button hooks, zipper pull, long-handled shoe horn)

☐

Other (specify):

PLEASE TICK ANY CATEGORIES FOR WHICH YOU USUALLY NEED HELP FROM ANOTHER PERSON:

Dressing and grooming

☐

Eating

☐

Arising

☐

Walking

☐

Please tick the response which best describes your usual abilities over the past week

	Without ANY difficulty ⁰	With SOME difficulty ¹	With MUCH difficulty ²	UNABLE to do ³	CATEGORY SCORE
--	--	--------------------------------------	--------------------------------------	------------------------------	-------------------

5. HYGIENE (H)

Are you able to:

a. Wash and dry your body?

☒
☐
☐
☐

b. Take a bath?

☒
☐
☐
☐

c. Get on and off the toilet?

☒
☐
☐
☐

6. REACH (R)

Are you able to:

a. Reach and get down a 5 lb object
(e.g. a bag of potatoes) from just
above your head?

☒
☐
☐
☐

b. Bend down to pick up clothing
off the floor?

☒
☐
☐
☐

7. GRIP (G)

Are you able to:

a. Open car doors?

☒
☐
☐
☐

b. Open jars which have been
previously opened?

☒
☐
☐
☐

c. Turn taps on and off?

☒
☐
☐
☐

8. ACTIVITIES (A)

Are you able to:

a. Run errands and shop?

☒
☐
☐
☐

b. Get in and out of a car?

☒
☐
☐
☐

c. Do chores such as vacuuming,
housework or light gardening?

☒
☐
☐
☐

PLEASE TICK ANY AIDS OR DEVICES THAT YOU USUALLY USE FOR ANY OF THESE ACTIVITIES:

Raised toilet seat (H)

☐

Bath seat (H)

☐

Bath rail (H)

☐

Long-handled appliances for reach (R)

☐

Long-handled appliances in bathroom (R)

☐

Jar opener (for jars previously opened) (G)

☐

Other (specify) _____

PLEASE TICK ANY CATEGORIES FOR WHICH YOU USUALLY NEED HELP FROM ANOTHER PERSON:

Hygiene

☐

Gripping and opening things

☐

Reach

☐

Errands and housework

☐

O.P. CLINICAL NOTES
(Medical)

NUMBER

600101156L F 06/11/1975

NAME

Halliday, Shona
16 Thornybank grove,
Dalkeith,
Midlothian,
EH22 1AP

CHI 0611751143
77197 D Robertson

DATE

SHEET No.

17 Feb 2014 E10887 Scottish Early Rheumatoid Arthritis
(SERA) inception and biobank. Ref
no: 2010/WIRH/01 subject number 1131
Patient attended WTCRF to participate in
the above study. Patient deemed
eligible to participate by Dr McKay
Informed consent obtained by myself
and questions answered. DAS 44
performed 0 - tender; 1 swollen
Blood and urine samples obtained Data
collection sheet completed. GP letter sent
out. Consent and PIS signed in notes
6 month appointments arranged for
18 Aug 2014  Roz Jones RESEARCH
NURSE

[illegible]

O.P. CLINICAL NOTES

NUMBER

07835500314 (Medical)

0485

NAME Shana Halleday

0131 454 0485
current

DATE

SHEET No.

17/2/14

Good response from @ first injection

Consider the following 12 hrs & order (2mg as

with the camera used treatment - No steroids
Fever 6-7/5 case

Nyl

7

8/4/14

WT 76. Kgs

SCURRI CSW-OPD.

BP 131/70.

HR. 96.

Mini post Ar ✓

Mild long steady ↓ Sng - sweats (Mk contin) Abnormal Sweats
MTR 15mg daily / fever and Sng weekly 2 y/s

Other 200g BO

Under gynae.

No pain killers

impaired shoulder wrists & foot

no loss

Sleep not disturbed

no dry cough - slight cough due to cold 1/52

No breathlessness

Spit yellow-green - improving Cough improving

U/s to SO via 18 SMO =

Plan - prednisone 5mg daily in 1/5
for 5/5

MTR 15g

Other 200g BO

Trying to stop smoking

Shona Gammonch

DATE

22/5/14 wt: 78kg
BP 131/69
P 82

1

M Walker

HR 150 / pulse 82

Other 250mg AD

pred 5mg daily dose 1/2

was hand 3hs

No myopia - changed to hla

parental x 2 AD

hands wrist lower back hips

① knee

ACL ligament

excised / physio

o/p TO 50 ASA IV SPS 75 ~ 3.07

ph

from 15-20mg / hla and

from on other 20mg

physio - advise re being active

lower back pain / physio

disorder in hips

some urgency

itch on both legs / physio

start within 2 days

1/4 Depo Pen

1/12

ph

Shona Gammonch

3/7/14 wt - 74Kgs
B.P - 127/79
Pulse - 91

Musea SP

O.P. CLINICAL NOTES

(Medical)

NUMBER 600101156L F 06/11/1975
 Halliday, Shona
 NAME 16 Thornybank grove,
 Dalkeith,
 Midlothian,
 EH22 1AP
 CHI 0611751143
 77197 D. Robertson

DATE

SHEET No.

3/7/14 1/2 back and hip on a daily basis along capsule
 into ok

normal, anti-infective test - but substituted presently

over 20% weekly follow and -

other 20% BTB

Pharmaceutical x 4 daily

stay at doctor's

Am - find @ prices

possible back to work

when child becomes 5

1st of reduced @ 1/4

along becoming stable

0/0

TU 50 CSN 14 5/10 = 1.99

plan

time max 20% / 1/10/10

other 20% 1/10

phys. 1/10 1/10

blood monitoring monthly

Review 1/10

1/10

DATE

Rheumatology

11/9/14

BP 110/71

P 94

wt 73.3kg.

SOA: no rxn

Haterson SW

thick skin generally legs flaps/buck of Gynops 7-4/12
near a rock

speaking 1st 7-4 tons a week

BSA not helped. cool feet helped
SATA within hour.

100% 20g weekly / 100% air

0.1% 200g SD

shp rock legs 1/10g looking okay

① foot

Pericardial / 10g/week

3-4/12 100% legs

o/o T 100% 100% 100%

S

BSA 1/4

JMS 25

ph

Single end back pressure

10mg 100% 100% - 100% 100%

100% 100% 100%

0.1% 200g SD

1M 100% 100%

100% 100% 100%

100% 100% 100%

100%

O.P. CLINICAL NOTES

(Medical)

NUMBER 0611751143

NAME

Shona Halliday

~~600101156L~~ 600101156L

DATE

SHEET No.

11 SEP
2014

SERA study, CRF E10887, R+D no: 2010/W/RH/01, subject no: 1131. Attended WTCRF today for 6 month visit of above study. Happy to continue in study. All questionnaires completed. Con-meds noted. TLC-2, SJC-0. Study blood and urine samples obtained, also bloods obtained for local MTX monitoring. Arrangements made for next study visit.

E. Whitecross
E. WHITECROSS
Research Nurse
WT-CRF

28 JAN 15

Sera Study CRF E10887 R+D no: 2010/W/RH/01 Subject no 1131

Participant telephoned WTCRF today + Report feeling well

Medications working well + Now all follow up clinic appointments

to be at a different hospital location. Therefore participant

cancelled Appt on the 5 Feb 2015 At WTCRF + wishes to

Withdraw from Study. Forwarded Message over to WTCRF

Project Assistant.

S. Lunn

S. LUNN

Research Nurse.

WTCRF

[illegible]

EH22-1AP

CHI 0611751143

77197

D Robertson

Clinitek Status

Serial Number:

54292

Patient:

Multistix® 10 SG

Test date 03-02-2014

Time 4:31PM

Operator

Test number 1994

Color Not Entered

Clarity Not Entered

GLU Negative

BIL Negative

KET Negative

SG 1.010

*BLO 2+ *

pH 5.5

PRO Negative

UBG 3.2 umol/L

NIT Negative

LEU Negative

Siemens

Clinitek Status®

Serial Number:

54292

Patient:

SHONA MALLIDAY

Multistix® 10 SG

Test date 08-10-2012

Time 2:52PM

Operator

Test number 4087

Color Not Entered

Clarity Not Entered

GLU Negative

BIL Negative

KET Negative

SG 1.010

*BLO 1+ *

pH 6.5

PRO Negative

UBG 3.2 umol/L

NIT Negative

LEU Negative

Midlothian,

EH22-1AP

CHI 0611751143

77197

S Ahmed

Serial Number:

54292

Patient:

Multistix® 10 SG

Test date 22-05-2014

Time 10:42AM

Operator

Test number 3445

Color Not Entered

Clarity Not Entered

GLU Negative

BIL Negative

KET Negative

SG 1.010

*BLO 2+ *

pH 6.0

PRO Negative

UBG 3.2 umol/L

NIT Negative

LEU Negative

Dalketh,

Midlothian,

EH22-1AP

CHI 0611751143

77197

S Ahmed

Serial Number:

38880

Patient:

Multistix® 10 SG

Test date 21-01-2015

Time 1:06PM

Operator

Test number 7762

Color Not Entered

Clarity Not Entered

GLU Negative

BIL Negative

KET Negative

SG >=1.030

BLO Negative

pH 7.0

*PRO Trace *

UBG 3.2 umol/L

NIT Negative

LEU Negative

O.P. CLINICAL NOTES
(Medical)

NUMBER 600101156L F 06/11/1975
NAME Halliday, Shona
16 Thornybank grove,
Dalkeith,
Midlothian,
EH22 1AP
CHI 0611751143 77197 D. Robertson

DATE

SHEET No.

21/1/15, Bl. 120/73. P. 107.
WT - 77Kg.

SON

Kay

- Mayhew Feb 2014

- MTX 20mg
fa.

- HCQ 200²
↳ ↓ ↑

- uncontrolled episodes
↓
↓

- high bae ↓

PGS 5
ESR 14
SR 0
TS 0
↓
P. 42

MT only

→ Exithena ✓

Not anti

DATE _____

[illegible]

OTHER MEDICINE CHARTS IN USE		PREVIOUS ADVERSE REACTIONS This section must be completed before any medicine is given		Completed by (sign & print)	Date
Date	Type of Chart	None known ☐			
		Medicine / Agent	Description of reaction		

- Write the medicine dose clearly
 - The only acceptable abbreviations are:
 g - gram mg - milligram ml - millilitre
 all other doses must be written out in full eg. micrograms
 - Avoid decimal points eg. 100 micrograms (not 0.1 mg). If unavoidable, write zero in front of the decimal point
 - Prescribe liquids by writing the dose in mg
 - For 'as required' medicines, state the symptoms to be relieved, the minimum time interval between doses and the maximum daily dose
 - Write units as 'units' not 'iu'

Review Date: June 2014 PRN 002

CODES FOR NON-ADMINISTRATION OF PRESCRIBED MEDICINE
 If a dose is not administered as prescribed, initial and enter a code in the column with a circle drawn round the code according to the reason as shown below. Inform the responsible doctor in the appropriate timescale.

1. Patient refuses
2. Patient not present
3. Medicines not available - CHECK ORDERED
4. Asleep / drowsy
5. Administration route not available - CHECK FOR ALTERNATIVE

6. Vomiting / nausea
7. Time varied on doctor's instructions
8. Once only / as required medicine given
9. Dose withheld on doctor's instructions
10. Possible adverse reaction / side effect

O X Y G E N	Start		Route		Prescriber - Sign + Print	Administered by	Stop	
	Date	Time	Mask (%)	Prongs (l/min)			Date	Time

PRESCRIPTION		Patient's Own Medicine	Date→																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																			
--------------	--	------------------------	-------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Page 3 of 6

PRESCRIPTION		Patient's Own Medicine	AS REQUIRED THERAPY																
Medicine (Approved Name)		For use	Date																
			Time																
Dose + frequency + max	Route	Quantity	Dose																
			Initials																
Indication + notes	Start Date	Date	Date																
			Time																
Prescriber - sign + print		Pharmacy	Dose																
			Initials																
Medicine (Approved Name)		For use	Date																
			Time																
Dose + frequency + max	Route	Quantity	Dose																
			Initials																
Indication + notes	Start Date	Date	Date																
			Time																
Prescriber - sign + print		Pharmacy	Dose																
			Initials																
Medicine (Approved Name)		For use	Date																
			Time																
Dose + frequency + max	Route	Quantity	Dose																
			Initials																
Indication + notes	Start Date	Date	Date																
			Time																
Prescriber - sign + print		Pharmacy	Dose																
			Initials																
Medicine (Approved Name)		For use	Date																
			Time																
Dose + frequency + max	Route	Quantity	Dose																
			Initials																
Indication + notes	Start Date	Date	Date																
			Time																
Prescriber - sign + print		Pharmacy	Dose																
			Initials																
Medicine (Approved Name)		For use	Date																
			Time																
Dose + frequency + max	Route	Quantity	Dose																
			Initials																
Indication + notes	Start Date	Date	Date																
			Time																
Prescriber - sign + print		Pharmacy	Dose																
			Initials																
Medicine (Approved Name)		For use	Date																
			Time																
Dose + frequency + max	Route	Quantity	Dose																
			Initials																
Indication + notes	Start Date	Date	Date																
			Time																
Prescriber - sign + print		Pharmacy	Dose																
			Initials																

PRESCRIPTION		Patient's Own Medicine	AS REQUIRED THERAPY																	
Medicine (Approved Name)		For use	Date																	
			Time																	
Dose + frequency + max	Route	Quantity	Dose																	
			Initials																	
Indication + notes	Start Date	Date	Date																	
			Time																	
Prescriber - sign + print		Pharmacy	Dose																	
			Initials																	
Medicine (Approved Name)		For use	Date																	
			Time																	
Dose + frequency + max	Route	Quantity	Dose																	
			Initials																	
Indication + notes	Start Date	Date	Date																	
			Time																	
Prescriber - sign + print		Pharmacy	Dose																	
			Initials																	
Medicine (Approved Name)		For use	Date																	
			Time																	
Dose + frequency + max	Route	Quantity	Dose																	
			Initials																	
Indication + notes	Start Date	Date	Date																	
			Time																	
Prescriber - sign + print		Pharmacy	Dose																	
			Initials																	
Medicine (Approved Name)		For use	Date																	
			Time																	
Dose + frequency + max	Route	Quantity	Dose																	
			Initials																	
Indication + notes	Start Date	Date	Date																	
			Time																	
Prescriber - sign + print		Pharmacy	Dose																	
			Initials																	
Medicine (Approved Name)		For use	Date																	
			Time																	
Dose + frequency + max	Route	Quantity	Dose																	
			Initials																	
Indication + notes	Start Date	Date	Date																	
			Time																	
Prescriber - sign + print		Pharmacy	Dose																	
			Initials																	
Medicine (Approved Name)		For use	Date																	
			Time																	
Dose + frequency + max	Route	Quantity	Dose																	
			Initials																	
Indication + notes	Start Date	Date	Date																	
			Time																	
Prescriber - sign + print		Pharmacy	Dose																	
			Initials																	

REGULAR THERAPY

[illegible]

TURN OVER

**Bone mineral density
(BMD) measurements**



**Osteoporosis
Service**

Study date:
12 September 2014

Surname: Halliday Forename: Shona Date of Birth: 06/11/1975
Hospital: WGH Consultant: DR NEIL DOUGLAS MCKAY CHI No: 0611751143 Age: 38

DIAGNOSIS

	BMD g/cm ²	T-Score	WHO Diagnosis	% of age matched population with lower BMD	% Change since
Spine (L1,L2,L3,L4)	0.991	-0.5	Normal	38	
L Fem Neck	0.722	-1.1	Osteopenia	18	
L Total Hip	0.82	-1	Osteopenia	18	

For the sites measured the WHO category is: **OSTEOPENIA**


10 Year Fracture Risk

Hip Fracture Risk	0.7%
Major Osteoporotic Fracture Risk (spine, forearm, hip or shoulder)	4.3%

Ht(cm): 165 Wt(kg): 73

Evaluation of risk based on femoral
neck BMD, age and clinical risk factors
using the WHO Fracture Risk
Assessment Tool (FRAX)

10 year fracture risks calculated and
plotted using minimum possible age
for FRAX tool (40 years)



TREATMENT SUGGESTIONS Relevant factors: low dietary Ca

Current daily dietary calcium = 580mg (recommended daily intake is 1000mg)

Due to low calcium intake the patient should be advised to increase dietary calcium.

Lifestyle advice only is recommended.

Lifestyle advice: perform weight bearing exercise, avoid smoking and excessive alcohol intake, follow a healthy diet with adequate calcium and vitamin D. Patient information and advice is available from the National Osteoporosis Society (Helpline 0845 450 0230)

Treatment suggestions are generated using a computer program.

Handwritten signature
20/10/18

Report checked by: C. Sidey (Clinical Technologist)

Biochemistry Department

CHI: 0611751143

CONSULTANT/GP: Dr Neil D McKay

SENDER: mckay..

RA.

COMMENTS: Only comments on the most recent result are printed

DATE PRINTED: 04/02/2014
TIME PRINTED: 11:30

PATIENT: HALLIDAY SHONA UPI: 600101156L CHI:
 DOB: 06/11/1975 SEX: F CONSULTANT/GP: Dr Neil D McKay
 SOURCE: WGH 1st Floor, Outpatient Dept SENDER: mckay..

CLINICAL SPECIALTY: Rheumatology

Date Collected	17/07/13	26/11/13	26/11/13	03/02/14	03/02/14
Time Collected	10:35	09:35	09:35	15:52	15:52
Date Received	17/07/13	26/11/13	26/11/13	03/02/14	03/02/14
Time Received	17:07	12:58	13:36	17:31	17:35
Specimen Number	HB942660	HR287965	HR292031	QB202267	QB202266
Haemoglobin	115-160 g/L		129		124
Red cell count	3.8-5.8 $10^{12}/L$		4.04		4.06
Haematocrit	0.37-0.47 Ratio		0.372		0.380
Mean cell volume	78-98 fl		92		94
White cell count	4-11 $10^9/L$		8.8		8.3
Neutrophil Count	2-7.5 $10^9/L$		5.76		4.84
Lymphocyte Count	1.5-4 $10^9/L$		2.43		2.88
Monocyte Count	0.2-0.8 $10^9/L$		0.50		0.47
Eosinophil Count	0.04-0.4 $10^9/L$		0.09		0.11
Basophil Count	0.01-0.1 $10^9/L$		0.03		0.04
Platelet count	150-350 $10^9/L$		243		289
ESR	3-15 mm/hr		19		18
Ferritin	15-200 ug/L	34			

COMMENTS:

Results outwith the reference range are highlighted in BOLD

Results obtained from Serum, Plasma or Whole Blood
 unless otherwise stated.

DATE PRINTED: 4Feb14
 TIME PRINTED: 12:30

LOTHIAN UNIVERSITY HOSPITALS DIVISION

Western General Hospital, EH4 2XU. Tel: 0131 537 1909

Biochemistry Department

PATIENT: HALLIDAY, SHONA DOB: 06/11/1975 SEX: F SOURCE: WGH 1st Floor, Outpatient Dept	UPI: 600101156L CHI: 0611751143 CONSULTANT/GP: Dr Neil D McKay SENDER: mckay..
--	--

CLINICAL DETAILS: Speciality : Rheumatology

RA.....

Date Collected	08/10/2012	17/07/2013	17/07/2013	26/11/2013	03/02/2014
Time Collected	15:11	10:35	10:35	09:35	15:52
Date Received	08/10/2012	17/07/2013	17/07/2013	26/11/2013	03/02/2014
Time Received	17:20	17:07	17:07	14:07	17:29
Specimen Number	QB312929R	HB942660D	HB942663Z	HB984187Q	QB202261J
Urea	2.5-6.6 mmol/L	2.9	3.5	3.1	3.5
Creatinine	60-120 umol/L	51 L	54 L	62	58 L
eGFR (/1.73m2)	ml/min	>60	>60	>60	>60
Sodium	135-145 mmol/L	139	142	138	140
Potassium	3.6-5 mmol/L	4.1	4.1	4.3	3.8
Glucose	mmol/L		4.7		
Spec type Rand/Fast Limits			Rand(<11)		
Bilirubin	3-21 umol/L	6	3		4
ALT	10-50 U/L	13	14		16
Alk.Phos	40-125 U/L	87	89		93
GGT	5-35 U/L		15		
Albumin	30-45 g/L	42			39
Calcium	2.1-2.6 mmol/L	2.39			2.40
Adjusted Calcium	2.1-2.6 mmol/L	2.35			2.42
Cholesterol	mmol/L				6.1
Triglyceride	0.8-2.1 mmol/L				3.7 H
HDL Chol.	1.1-1.7 mmol/L				1.1
LDL Chol.	mmol/l				3.3
Chol:HDL Ratio					5.5
CK	30-135 U/L	89			
Urate	0.12-0.36 mmol/L			0.26	0.27
Ferritin	15-200 ug/L		34		
Total Protein	60-80 g/L	74			
IgG	6-15 g/L	8.29			
IgA	0.8-4.5 g/L	1.65			
IgM	0.35-2.9 g/L	1.56			
Prot E'phoresis		COMMENT			
C-Reactive Prot	mg/L				<1
TSH	0.2-4.5 mU/L	5.4 H	2.9		
Free T4	9-21 pmol/L	12	12		
Anti-tTG IgA (DS2)	0.1-5.0 U/mL	0.5			0.24
M1/2					

COMMENTS: Only comments on the most recent result are printed

DATE PRINTED: 08/02/2014
TIME PRINTED: 11:30

Specimen type is serum, plasma or blood unless otherwise stated



SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE
Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA
Clinical Immunology 0131-242 7525 / 9

6/11/12 Letter 262
EDINBURGH & S.E. SCOTLAND BLOOD TRANSFUSION CENTRE



IMMUNOLOGY SERVICES

CLINICAL IMMUNOLOGY REPORT

SURNAME HALLIDAY D.O.B. 06/11/1975 LAB REG. No. HI876420P
Specimen: Blood
FORENAME/S SHONA DATESAMPLE TAKEN 08/10/2012 15:11
HOSPITAL NUMBER 600101156L DATE RECEIVED 09/10/2012 14:05

TEST	RESULT	NORMAL RANGE
Classical Complement Pathway	93.8	%Activity(47.6 - 130.4)
Please note that this assay has an absolute requirement for serum and so plasma samples are not tested. However, if the Lab has received a pre-aliquoted sample (this will be stated at the foot of this report) it is not possible to determine its coagulation status and therefore the result may be unreliable.		
C3	1.82	g/l (0.81 - 1.57)
A decrease in C3 can be caused by activation of both the classical and alternative pathways. Thus it can follow from immune complex disease (eg. systemic lupus erythematosus) or acute bacterial infection (eg. post-streptococcal glomerulonephritis). Serial determinations are sensitive monitors of disease activity. Persistent low levels can rarely be due to the presence of C3 nephritic factor. C3 is also an acute-phase protein and therefore levels can be raised in infection, inflammation or injury. This increase can mask increased consumption of C3.		
C4	0.40	g/l (0.13 - 0.39)
C4 is a protein of the classical complement pathway and is therefore activated in immune complex disease. C4 null alleles are common and affect the baseline levels. It cannot therefore be used as a marker of activity in systemic lupus erythematosus but serial determinations can be used to monitor disease activity. A low C4 together with a low C1 Esterase Inhibitor is strongly suggestive of hereditary angioedema. C4 is often reduced in pre-eclampsia. C4 is also an acute-phase protein and therefore levels can be raised in infection, inflammation or injury. This increase can mask increased consumption of C4.		
Rheumatoid Factor	42.2	IU/ml (0 - 20)
IgM Rheumatoid factor found in ~80% of patients with active Rheumatoid Arthritis. Can be found in other conditions or the elderly and are not significant unless patient has synovitis.		

Further details in Laboratory Handbook at <http://www.scotblood.co.uk/publications.asp>

REPORT TO BE RETURNED TO:

Dr Mohini K Gray
WGH 1st Floor, Outpatient Dept
Western General Hospital
Crewe Road South

DATE REPORTED

17/10/2012
15:02

SIGNATURE:

CONSULTANT CLINICAL SCIENTIST 0131 242 7535
PLEASE PHONE FOR DISCUSSION OF RESULTS IF NECESSARY



IMMUNOLOGY SERVICES

CLINICAL IMMUNOLOGY REPORT

SURNAME HALLIDAY O.O.B. 06/11/1975 LAB REG.No. HI876420P
Specimen: Blood
FORENAME/S SHONA DATE SAMPLE TAKEN 08/10/2012 15:11
HOSPITAL NUMBER 600101156L DATE RECEIVED 09/10/2012 14:05

TEST	RESULT	NORMAL RANGE
Cyclic Citrullinated Peptide	471.0	u/ml (0 - 4.8)

Anti-CCP antibodies are more specific than Rheumatoid Factor for diagnosing Rheumatoid Arthritis(RA) and are present in approximately 70% of early stage RA patients. They are good predictors of radiographic joint disease and may be useful in discriminating between erosive osteoarthritis and RA. These antibodies may be present up to 10 years prior to diagnosis and so are highly predictive of the future development of RA in both healthy subjects and patients with undifferentiated arthritis. Anti-CCP are only rarely found in patients with Juvenile Idiopathic Arthritis and are not associated with Lupus Arthropathy but their presence in Sjogren's Syndrome is indicative of future RA. In patients with clinical symptoms of Polymyalgia Rheumatica their presence is strongly suggestive of elderly onset RA. Anti-CCP occur in a subgroup of patients with type 1 autoimmune hepatitis who have a greater occurrence of cirrhosis at presentation and higher incidence of death from hepatic failure.

Anti ds DNA	6.6	IU/ml (0 - 15)
-------------	-----	----------------

ENA Screen	Negative
------------	----------

This sample has been screened for antibodies to Ro, La, Sm, RNP, Scl70 and Jo1 and is negative for all of them.

Test Refusal	Not Tested
--------------	------------

One of the autoantibodies listed below has been requested. These autoantibodies can be present many years after diagnosis and do not respond to treatment. Consequently, frequent repeat testing cannot be justified. A previous request for one of these autoantibodies to be tested in this patient has been made within the last 6 months and has therefore been denied on this occasion.

Anti-Nuclear Antibody(ANA), Extractable Nuclear Antibody (ENA), Thyroid Peroxidase Antibody(TPO), Intrinsic Factor Antibody(IFA), Steroid Cell Antibodies(Ovary, Testes, Adrenal), Gastric Parietal Cell Antibody(GPC),

Further details in Laboratory Handbook at <http://www.scotblood.co.uk/publications.asp>

REPORT TO BE RETURNED TO:

Dr Mohini K Gray
WGH 1st Floor, Outpatient Dept
Western General Hospital
Crewe Road South

DATE REPORTED

17/10/2012
15:02

CONSULTANT CLINICAL SCIENTIST 0131 242 7535
PLEASE PHONE FOR DISCUSSION OF RESULTS IF NECESSARY

SIGNATURE:



IMMUNOLOGY SERVICES

CLINICAL IMMUNOLOGY REPORT

SURNAME HALLIDAY D.O.B. 06/11/1975 LAB REG. No. HI876420P
Specimen: Blood
FORENAME/S SHONA DATE SAMPLE TAKEN 08/10/2012 15:11
HOSPITAL NUMBER 600101156L DATE RECEIVED 09/10/2012 14:05

TEST

RESULT

NORMAL RANGE

Mitochondrial Antibody (AMA), Liver Kidney Microsomal
Antibody (LKM1), Glutamic Acid Decarboxylase Antibody
(GAD), Insulinoma Antigen 2 Antibody (IA2).
If you would like to discuss this further please call
Dr Mick Kadlubowski on 0131 242 7535.

Specimen Comment: -
8332IANA TEST REFUSED

Further details in Laboratory Handbook at <http://www.scotblood.co.uk/publications.asp>


REPORT TO BE RETURNED TO:

Dr Mohini K Gray
WGH 1st Floor, Outpatient Dept
Western General Hospital
Crewe Road South

DATE REPORTED

17/10/2012
15:02

CONSULTANT CLINICAL SCIENTIST 0131 242 7535
PLEASE PHONE FOR DISCUSSION OF RESULTS IF NECESSARY

SIGNATURE: 

600101156L
478 1463
07842106962

File HR

NHS Lothian

**WESTERN GENERAL HOSPITAL
RADIOLOGY CLINICAL REPORT**

PATIENT NAME:	Halliday	Shona	UHPI:	600101156L
----------------------	----------	-------	--------------	------------

CHI: 0611751143

Order Items:

MRI Hand Lt

MRI Hand Rt

MRI Wrist Lt

MRI Wrist Rt

Clinical details

bilateral hands and wrists pain, inflammatory history but no overt synovitis, CCP positive, High ESR, please look for subclinical synovitis.

MRI Both Hands & Wrists

Coronal T1W and PD fat sat imaging has been obtained from distal forearms to fingertips.

There are normal appearances to distal radius and ulnar, carpus, metacarpals and phalanges with no bony erosions evident. The articulations in wrists and hands appear unremarkable, with no joint effusions. No overt periarticular soft-tissue thickening or oedema / inflammation and no overt synovitis.

Normal musculotendinous appearances bilaterally.

Reported by Dr M L Errington.

M4 → Flu

ADDRESS:	16 Thornybank grove	DOB:	06/11/1975
	Dalkeith	SEX:	Female
	EH22 1AP		

REFERRER:	
ADDRESS:	

Episode Consultant:	Dr MK Gray
Order Patient Location:	WGH 1st Floor, Outpatient Department
Receiving Location:	WGH - MRI

Order Items(s):	Visit No	Date of Exam	Referring Clinician
MRI Hand Lt	13451376	06/11/2012	Dr MK Gray
MRI Hand Rt	13451376	06/11/2012	Dr MK Gray
MRI Wrist Lt	13451376	06/11/2012	Dr MK Gray
MRI Wrist Rt	13451376	06/11/2012	Dr MK Gray

D.O.R:	06/11/2012	Reporting Radiologist:	Dr Martin Errington
D.O.T:	06/11/2012	Overseen by Radiologist:	
D.O.V:	06/11/2012	Verifying Radiologist:	Dr Martin Errington
		Typist/Secretary:	Anna Mitchell
		Radiologist Signature:	

Printed 06/11/2012 16:23:47

WESTERN GENERAL HOSPITAL

RADIOLOGY CLINICAL REPORT

PATIENT NAME:	Halliday	Shona	UHPI:	600101156L
----------------------	----------	-------	--------------	------------

CHI: 0611751143

Order Items:

XR Chest

XR Hands

XR Feet

Clinical details

XR Chest, XR Hands, XR Feet

RA pre MTX


Report

Normal heart and mediastinal contours. Lungs clear with normal pulmonary vascularity.

No significant abnormality of either hand. No erosions.

Erosion of the head of the left first metatarsal and also the base of the proximal phalanx of the left great toe.

Reported by Dr Domenyk Brown



ADDRESS:	16 Thornybank grove	DOB:	06/11/1975
	Dalkeith	SEX:	Female
	EH22 1AP		

REFERRER:	
ADDRESS:	

Episode Consultant:	Dr Neil Douglas McKay
Order Patient Location:	WGH 1st Floor, Outpatient Department
Receiving Location:	WGH - Main X-Ray

Order Items(s):	Visit No	Date of Exam	Referring Clinician
XR Chest	17127530	03/02/2014	Dr Neil Douglas McKay
XR Hands	17127530	03/02/2014	Dr Neil Douglas McKay
XR Feet	17127530	03/02/2014	Dr Nei

D.O.R:		Reporting Radiologist:	Dr Domenyk Brown
D.O.T:	03/02/2014	Overseen by Radiologist:	
D.O.V:	03/02/2014	Verifying Radiologist:	Dr Domenyk Brown
		Typist/Secretary:	Dr Domenyk Brown
		Radiologist Signature:	

Printed 03/02/2014 17:16:50



IMMUNOLOGY SERVICES

CLINICAL IMMUNOLOGY REPORT

SURNAME HALLIDAY D.O.B. 06/11/1975 LAB REG. No. HI931256W
Specimen: Blood
FORENAME/S SHONA DATE SAMPLE TAKEN 03/02/2014 15:52
HOSPITAL NUMBER 600101156L DATE RECEIVED 04/02/2014 13:31

TEST

RESULT

NORMAL RANGE

CH50 (haemolytic Complement) Insufficient Sample
C3 1.74 g/l (0.81 - 1.57)

A decrease in C3 can be caused by activation of both the classical and alternative pathways. Thus it can follow from immune complex disease (eg. systemic lupus erythematosus) or acute bacterial infection (eg. post-streptococcal glomerulonephritis). Serial determinations are sensitive monitors of disease activity. Persistent low levels can rarely be due to the presence of C3 nephritic factor. C3 is also an acute-phase protein and therefore levels can be raised in infection, inflammation or injury. This increase can mask increased consumption of C3.

C4 0.35 g/l (0.13 - 0.39)

C4 is a protein of the classical complement pathway and is therefore activated in immune complex disease. C4 null alleles are common and affect the baseline levels. It cannot therefore be used as a marker of activity in systemic lupus erythematosus but serial determinations can be used to monitor disease activity. A low C4 together with a low C1 Esterase Inhibitor is strongly suggestive of hereditary angiodema. C4 is often reduced in pre-eclampsia. C4 is also an acute-phase protein and therefore levels can be raised in infection, inflammation or injury. This increase can mask increased consumption of C4.

Rheumatoid Factor 56.9 IU/ml (0 - 20)

IgM Rheumatoid factor found in ~80% of patients with active Rheumatoid Arthritis. Can be found in other conditions or the elderly and are not significant unless patient has synovitis.

Cyclic Citrullinated Peptide 335.0 U/ml (0 - 4.8)

Anti-CCP antibodies are more specific than Rheumatoid Factor for diagnosing Rheumatoid Arthritis (RA) and are present in approximately 70% of early stage RA patients. They are good predictors of radiographic joint disease and may be useful in discriminating between erosive

Further details in Laboratory Handbook at <http://www.scotblood.co.uk/publications.asp>

REPORT TO BE RETURNED TO:

Dr Neil D McKay
WGH 1st Floor, Outpatient Dept
Western General Hospital
Crewe Road South

DATE REPORTED

14/02/2014
17:16

SIGNATURE: *[Signature]*

CONSULTANT CLINICAL SCIENTIST 0131 242 7535
PLEASE PHONE FOR DISCUSSION OF RESULTS IF NECESSARY



IMMUNOLOGY SERVICES

CLINICAL IMMUNOLOGY REPORT

SURNAME HALLIDAY D.O.B. 06/11/1975 LAB REG. No. HI931256W
Specimen: Blood
FORENAME/S SHONA DATE SAMPLE TAKEN 03/02/2014 15:52
HOSPITAL NUMBER 600101156L DATE RECEIVED 04/02/2014 13:31

TEST

RESULT

NORMAL RANGE

osteoarthritis and RA. These antibodies may be present up to 10 years prior to diagnosis and so are highly predictive of the future development of RA in both healthy subjects and patients with undifferentiated arthritis. Anti-CCP are only rarely found in patients with Juvenile Idiopathic Arthritis and are not associated with Lupus Arthropathy but their presence in Sjogren's Syndrome is indicative of future RA. In patients with clinical symptoms of Polymyalgia Rheumatica their presence is strongly suggestive of elderly onset RA. Anti-CCP occur in a subgroup of patients with type 1 autoimmune hepatitis who have a greater occurrence of cirrhosis at presentation and higher incidence of death from hepatic failure.

Anti Nuclear Antibody Negative

ENA Screen Negative

This sample has been screened for antibodies to Ro, La, Sm, RNP, Scl70 and Jo1 and is negative for all of them.

Specimen Comment: -
mckay..

Further details in Laboratory Handbook at <http://www.scotblood.co.uk/publications.asp>

REPORT TO BE RETURNED TO: Dr Neil D McKay
WGH 1st Floor, Outpatient Dept
Western General Hospital
Crewe Road South

DATE REPORTED

14/02/2014
17:16

CONSULTANT CLINICAL SCIENTIST 0131 242 7535
PLEASE PHONE FOR DISCUSSION OF RESULTS IF NECESSARY

SIGNATURE:

LOTHIAN UNIVERSITY HOSPITALS DIVISION MEDICAL MICROBIOLOGY SERVICES

Specialist Virology Centre
Royal Infirmary of Edinburgh, 51 Little France Crescent
EDINBURGH EH16 4SA

PIN/CHI: 600101156L / 0611751143

D.O.B: 06/11/1975

Tel: 0131 242 6004/6027
0131 242 6029/6048
Internal 26004/26029

Patient: HALLIDAY, SHONA

Sex: Female

Report to: Dr Neil D McKay
mckay..

Date Taken: 03/02/2014

Time Taken: 15:52

Address: WGH 1st Floor, Outpatient Dept

Date Received: 04/02/2014

Time Received: 11:27

RA.....

Sending Laboratory Reference Number:

Date Reported: 11/02/2014

Laboratory Number: MS267269G

Specimen: Clotted blood for serology

Hep B surface Ag qualitative 0.25 S/CO

Hepatitis B surface Antigen : NEGATIVE

Anti-HBc Antibody: 0.06

Antibody to Hepatitis B core : NEGATIVE (Index <0.9)

Hepatitis C Antibody Index: 0.08

Antibody to Hepatitis C Virus : NEGATIVE (Index <0.9)

HIV Ag/Ab COMBO: 0.18

HIV Antigen/Antibody COMBO assay: NEGATIVE (Index <0.9)

1
K

Authorised by: Background Authorisation

for Dr J A G Bremner

'For ADULT SEROLOGY, RIE Virology is replacing analysis of white-capped clotted (serum) blood tubes with 7.5 ml S-Monovette Serum-Gel (Sarstedt) clotted (brown-capped) ones - product code 01.1602.001; ADULT MOLECULAR ANALYSIS should continue to be performed on 7.5 ml S-Monovette Potassium EDTA (Sarstedt) (red-capped) tubes - product code 01.1605.001. Thank you'



Western General Hospital,
Crewe Road South,
Edinburgh,
EH4 2XU

Tel 0131 5373387

Patient Consent Form

Study Title: ***Scottish Early Rheumatoid Arthritis (SERA)
inception cohort and biobank***

Name of Researcher: Dr Neil McKay

**Please initial
each statement**

1. I confirm that I have read and understood the information sheet (version 2.1) for the above study and any questions I have asked have been answered to my satisfaction
2. I understand that my participation is voluntary and that I am free to withdraw at any time, without giving reason, and without my medical care or legal rights being affected
3. I understand that sections of my medical notes may be looked at by responsible individuals who are either working on this study or from regulatory authorities where it is related to my taking part in this study. I give permission for these individuals to have access to my medical records

Yes, I
agree

No, I do
not agree

☒☐☒☐☒☐

- | | Yes, I agree | No, I do not agree |
|---|-------------------------------------|--------------------------|
| 4. I understand that my General Practitioner will be informed that I have agreed to participate in this study | ☒ | ☐ |
| 5. I agree to take part in the above study | ☒ | ☐ |
| 6. I agree that information about my health, including laboratory results, may be extracted from my NHS records now and in the future for health-related research purposes. | ☒ | ☐ |
| 7. I agree that I may be contacted to be asked to attend follow up study visits | ☒ | ☐ |
| 8. I agree that my urine, blood, DNA and joint fluid may be stored in the biobank, and that it may be analysed now or in the future. | ☒ | ☐ |
| 9. I agree that I may be contacted in the future about other research projects, but that I am under no obligation to take part in such projects | ☒ | ☐ |

S. Halliday
Signature of Participant

SHONA HALLIDAY
Print Name

17/2/14
Date

[Signature]
Signature of Person taking Consent

POZ STONES
Print Name

17 FEB 2014
Date

[Signature]
Signature of Researcher

Michael
Print Name

19 Feb 14
Date

Copy for case record/CRF/patient (delete as appropriate)

Date 18 Feb 2014

Dear Dr Ahmed

600101156L	F	06/11/1975
Halliday, Shona		
16 Thornybank grove,		
Dalkeith,		
Midlothian,		
EH22 1AP		
CHI 0611751143		
77197	S Ahmed	

Your patient has agreed to take part in the Scottish Early Rheumatoid Arthritis (SERA) cohort. This is a prospective inception cohort of patients with newly diagnosed RA or undifferentiated polyarthritis. Patients will have blood taken for a biobank at 0, 6 and 12 months and they will be reviewed clinically every 6 months indefinitely. The aim is to construct a detailed clinical database of patient outcomes that can be correlated with biomarkers that may allow the development of individualised protocols of management in the future.

You will be sent regular reports on the patient as part of their routine care but please don't hesitate to contact the department if you have any queries.

Many thanks,


ROZ JONES
RESEARCH NURSE
pp
Dr Neil McKay
Consultant Rheumatologist

MON 17/12/14 2pm letter sent 4/12/14 GP has same
app 1.25 Sun 33388 (M in the day to contact details NHS
after 5pm - Lothian

RHEUMATOLOGY NURSE SPECIALIST REFERRAL

☐ URGENT 2-4 days ☐ NON URGENT 4-14 days ☐ CNS REVIEW 3month

031 454 4085 PATIENT TELEPHONE: wrong no

600101156L F 06/11/1975 078 355 500 314 too many digits (P10)

PAT Halliday, Shona
DET 16 Thornybank grove,
Dalkeith,
Midlothian,
EH22 1AP
CHI 0611751143 - 4 FEB 2014
77197 S Ahmed

CONSULTANT: Miller
DIAGNOSIS: ERA + SERA

ERA & SERA REFERRAL

CXR taken?	YES	NO	SERA PI provided?	YES	NO	DAS28 taken?	YES	NO
Hands/feet Xray taken?	YES	NO	MTX/steroid PIL provided?	YES	NO	Patient asked to see GP 10 days hence	YES	NO
Bloods completed?	YES	NO	DEXA ordered?	YES	NO			

VISUAL ACUITY		DISEASE EDUCATION	DRUG COUNSELLING	PLEASE PRINT CLEARLY
AMSLER		Issue ARC leaflet/ website information	SWITCH to Subcut	DRUG: CRA
SCHIRMERS				DOSE: + SERA
SHORT SYNACTHEN				
SALIVA TEST				

PRESCRIPTION KARDEX REQUIRED AS APPROPRIATE PLEASE

SAB	GHJ	ELBOW	WRIST	KNEE	ANKLE
LT RT	LT RT	LT RT	RT LT	LT RT	LT RT

ADDITIONAL INFORMATION: PLEASE PRINT CLEARLY AVO 100 all PO steroids 17/2/14
(no oral steroids) M

DATE: 3/2/14 DOCTORS SIGNATURE: Miller

ABOVE REQUEST COMPLETED

VISUAL ACUITY	R	L	Disease / Drug Information given.	CNS SIGN: DATE: M/L 17/2/14
AMSLER	R	L		
SCHIRMERS	R	L	Drug counselling Check list to be issued to patient please.	TELEPHONE COUNSELLING
SHORT SYNACTHEN				PATIENT SIGN DATE:
SALIVA TEST				

JOINT ASPIRATED / INJECTED	AMOUNT RT	AMOUNT LT	CNS SIGN: DATE
AS PER PROTOCOL & PRESCRIPTION	COLOUR RT	COLOUR LT	PATIENT SIGN: DATE: